in vivo News and Research

RSS

Importance of residual thymopoiesis in aged adults

Doctor Manuel Leal is managing the Experimental Immune Virology Laboratory (in Virgen del Rocío University Hospital and Instituto de Biomedicina de Sevilla (IBIS), where clinic and basic science researchers work) where he leads a project to establish the functional nature of the thymus gland in adults. So far, it has been proven that this gland keeps on producing lymphocytes in the old age (Ferrando-Martínez et al. AGE, in press), which is a novelty because until very recently it was considered that this organ lost its immune capacity after the puberty.

22 Sep 2009

Research reveals binge drinking weakens the body's ability to fight off infection

As if a bad hangover wasn't enough of a deterrent, new research has shown how binge drinking weakens the body's ability to fight off infection for at least 24 hours afterwards. The study, published today in the open access journal BMC Immunology, focused on the effect of heavy drinking on toll-like receptor 4 (TLR4), a protein that has an important role in immune system activation.

17 Sep 2009

Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting

Medivir (STO:MVIRB) presented preclinical data on two candidate drugs (MIV-710, MIV-711) from its cathepsin K inhibitor program in a poster session during the ASBMR (American Society for Bone and Mineral Research) meeting.

16 Sep 2009

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will be presenting new in vivo data on its self-delivering rxRNA compounds at a number of upcoming scientific conferences, detailed below.

16 Sep 2009

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.

16 Sep 2009

NIBIB awards University of Miami a $735,000 grant to develop a bioreactor system for tissue engineering

A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.

16 Sep 2009

Calcium stones and cell death is linked to prolonged stressful conditions

Study shows prolonged stress sparks ER to release calcium stores and induce cell death in aging-related diseases such as atherosclerosis, diabetes and neurodegeneration

15 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

IVIS Lumina XR in vivo imaging system from Caliper Life Sciences

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family.

14 Sep 2009

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

Clinical data on CXA-101 to be presented at ICAAC

Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

arGEN-X BV announces first closing of its Series A equity financing round

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months.

10 Sep 2009

Nanotags pinpoint multiple cancer markers in live animals

Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford University Center for Cancer Nanotechnology Excellence [CCNE]) has shown that it can simultaneously track as many as 10 different optical tags in a living animal.

7 Sep 2009

StrataTest to be launched in the European market

Stratatech Corp., a privately-held regenerative medicine company, today announced that it will launch its StrataTest full-thickness human skin model to the European market at EUROTOX 2009, the annual meeting of the Federation of European Toxicologists and the European Societies of Toxicology. This year’s meeting is being held in Dresden, Germany, Sept. 13-16.

4 Sep 2009

NSF grants funds to develop next-generation nano-CT imaging system

In 1991, Ge Wang produced the first paper on spiral cone-beam computed tomography (CT), now an imaging technique used in the mainstream of the medical CT field. Today, Wang, known as a pioneer in this field, and his colleagues have been awarded more than $1.3 million from the National Science Foundation (NSF) to develop the next-generation nano-CT imaging system, which promises to greatly reduce the required dose of radiation.

4 Sep 2009

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009